Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2b dose-finding trial of subcutaneous LEO 138559 in adults with moderate-to-severe atopic dermatitis
jRCT2031230397Phase 2Completed
- Sponsor
- LEO Pharma
- Start
- Nov 2023
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
01
Overview
Phase 2, randomised, double-blind trial of temtokibart in atopic dermatitis (AD) (3 arms), sponsored by LEO Pharma. Primary endpoint: Percent change in Eczema Area and Severity Index (EASI) score from baseline to Week 16. Started Nov 2023; status: completed.
02
Drugs
temtokibart
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on jRCT2031230397.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031230397.